I9885
Anti-Human IgG (γ-chain specific), F(ab′)2 fragment antibody produced in goat
affinity isolated antibody, lyophilized powder
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
biological source
goat
Quality Level
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
secondary antibodies
clone
polyclonal
form
lyophilized powder
packaging
pkg of 5x1 mg
pkg of 1 mg
storage condition
avoid repeated freeze/thaw cycles
technique(s)
Ouchterlony double diffusion: suitable
quantitative precipitin assay: suitable
color
white to off-white
solubility
water: soluble, clear to hazy, colorless (after reconstitution with 1 ml of 0.135 M NaCl)
storage temp.
2-8°C
target post-translational modification
unmodified
Related Categories
General description
IgG antibody subtype is the most abundant serum immunoglobulins of the immune system. It is secreted by B cells and is found in blood and extracellular fluids and provides protection from infections caused by bacteria, fungi and viruses. Maternal IgG is transferred to fetus through the placenta that is vital for immune defence of the neonate against infections. Anti-Human IgG (γ-chain specific), F(ab′)2 fragment antibody is specific for human IgG subclasses. The F(ab′)2 fragment of the antibody is obtained from pepsin-digested antiserum by immunospecific methods of purification.
Immunogen
Purified human IgG
Application
Anti-Human IgG (γ-chain specific), F(ab′)2 fragment antibody is suitable for Ouchterlony double diffusion and quantitative precipitin assay. The antibody was used in ELISA and to produce Fab′-oligonucleotide conjugates.
Physical form
Lyophilized from 0.01 M sodium phosphate, 0.015 M sodium chloride, pH 7.2
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
H Brandstätter et al.
Vox sanguinis, 103(3), 201-212 (2012-04-14)
Complement factor H (CFH) acts as major regulator of the alternative pathway of complement and its mutations and polymorphisms predispose to various human diseases. We aimed to develop a scalable purification process of CFH from human plasma fractions to supply
Francesco Lolli et al.
Journal of neuroimmunology, 167(1-2), 131-137 (2005-07-30)
Synthetic glycopeptides have the potential to detect antibodies in multiple sclerosis (MS). In the present study, we analyzed the antibodies (IgM class, IgG class and IgG subclasses) to the synthetic glycopeptide CSF114(Glc) in the serum of 186 MS patients, 166
Hiroyasu Muramatsu et al.
Scientific reports, 11(1), 2160-2160 (2021-01-27)
Myostatin, a member of the transforming growth factor-β superfamily, is an attractive target for muscle disease therapy because of its role as a negative regulator of muscle growth and strength. Here, we describe a novel antibody therapeutic approach that maximizes
Z N Chaudri et al.
FEBS letters, 450(1-2), 23-26 (1999-06-01)
The covalent conjugation of oligonucleotides to antibody Fab' fragments was optimized by using oligonucleotides modified with a hexaethylene linker arm bearing three amino groups. One oligonucleotide was coupled to antibody of one specificity and a complementary oligonucleotide to antibody of
Christian Loch et al.
Journal of pharmaceutical sciences, 103(2), 517-526 (2013-12-07)
Intravitreal injections and drug-loaded implants are current approaches to treat diseases of the posterior eye. To investigate the release of active agents and their distribution in the vitreous body, a new test system was developed that enables a realistic simulation
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service